2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 651

Calprotectin Serum Levels Strongly Predict Disease Flare in RA and Psa Patients with Low Disease Activity Treated with TNF Inhibitors. a One-Year Prospective Cohort Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 681

Can Bridging Syndesmophytes Independantly Affect Spinal Mobility?

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 352

Can Lumbar Spine Bone Mineral Density Predict Readmission in Denosumab-Treated Chronic Kidney Disease Patients?

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 500

Can Thiol/Disulphide Is a Novel Marker in Rheumatoid Arthritis?

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 782

Can We Identify Who Benefits from Mycophenolate Mofetil in Systemic Lupus Erythematosus? a Systematic Review

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 614

Canadian Study of Outcomes in Adalimumab (HUMIRA®) Patients with Support for Adherence – Results from the Companion Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 830

Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

9:00AM-11:00AM: Abstract Number: 881

Cardiopulmonary Involvement in Takayasu Arteritis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 423

Cardiovascular Risk and Lipid Screening in Rheumatoid Arthritis Patients in a University Rheumatology Practice: Quality Improvement Project

Quality Measures and Quality of Care - Poster I

9:00AM-11:00AM: Abstract Number: 472

CCR6 Expression Regulates Arthritis in a T Cell Dependent Manner

Rheumatoid Arthritis – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 179

CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice

Innate Immunity and Rheumatic Disease - Poster I

9:00AM-11:00AM: Abstract Number: 581

Cell-Mediated Neutrophil Lysis-a Mechanism Promoting Hypercitrullination in Rheumatoid Arthritis?

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 350

Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 551

Changes in Diverse Disease Activity Measures Are Highly Correlated Following the Initiation of Most Treatment Modalities in the Management of Longstanding Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 353

Changes in Femoral Neck Bone Mineral Density Inverse Correlate with Egfr in Denosumab Treated Osteoporosis Patients? a Hospital-Based Analysis

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

«Previous Page
1
…
8
9
10
11
12
…
70
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].